Le Lézard
Classified in: Health
Subject: PER

dna Communications Names Mike Rosich New York General Manager


NEW YORK, Aug. 13, 2020 /PRNewswire/ -- dna Communications today announced the appointment of Mike Rosich as executive vice president, general manager, New York. Rosich joins dna from Marina Maher Communications, where he was executive director of creative strategy and storytelling. In his new role, Rosich will lead strategy and operations for the New York office, responsible for the growth of the agency's largest operation and for driving innovative solutions for clients. He will report to Laura Schoen, chief healthcare officer, Constituency Management Group, and president, Global Healthcare, Weber Shandwick.

"Mike is a driven leader and seasoned advisor whose unique background marries hard science with creativity ? an invaluable asset for our client partners and teams," Schoen said. "Since its founding nearly a decade ago, dna has grown at an impressive clip. With Mike at the helm in one of our key markets, we can accelerate that momentum and deliver greater business-building results to the agency as well as powerful solutions for our clients."

Over the course of his career, Rosich has excelled at collaboration and bridge-building, bringing together teams and expertise across the communications functions ? from digital strategy to content development to strategic planning ? to serve clients in entirely new, holistic efficient ways. In his most recent roles at Marina Maher Communications and RXMosiac, Rosich drove integrated, business-driving campaigns and developed digital healthcare offerings that fueled growth. Prior to that, he worked at healthcare advertising agencies Rosetta and Heartbeat.

Rosich has worked across a wide variety of therapeutic categories, including dermatology, women's health, oncology, vaccination, medical devices and health tech. He also has rich, diverse experience in consumer health, corporate communications and consumer goods.

"The impressive team at dna has carved a leading-edge niche in the healthcare space by breaking down complex concepts to create work that resonates deeply with key stakeholders," Rosich said. "I'm thrilled to be joining the dna family and look forward partnering with its fantastic client roster to help bring these stories to life."

dna delivers strategic, creative solutions that are grounded in science, yet accessible to a wide spectrum of stakeholders ? from patients and healthcare providers to policy makers and advocacy organizations. The agency has spearheaded influential campaigns on major health issues like addiction, cardiovascular disease, diabetes, macular degeneration, immunotherapy in oncology, evolving HIV treatment and multiple sclerosis. In partnership with its clients, dna's work has been recognized at the Cannes Lions International Festival of Creativity, the Clio Awards and PRovoke's SABRE Awards.

About dna Communications
dna Communications is a healthcare communications agency with unique thinking, insight and attitude. Through its patient-centric and science-first approach, dna helps its client partners negotiate the healthcare sector's ever-changing commercial, regulatory, scientific and communications landscape. dna is part of the Interpublic Group (NYSE: IPG). For more information, visit http://www.dna-comms.com/.

Contact: Sheila Zareh
Company: dna Communications
Phone: 212.537.8762
Email: [email protected]

 

 

SOURCE dna Communications


These press releases may also interest you

at 20:31
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...



News published on and distributed by: